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CLINICAL RESEARCH
A  single-centre  experience  concerning  the  safety  of
Sprint  Fidelis  deﬁbrillator  lead  extraction  at  the  time
of  pulse  generator  replacement  or  in  case  of
evidence  of  lead  failure
Extraction  systématique  des  sondes  de  déﬁbrillation  Sprint  Fidelis  lors  du
changement  de  boîtier  ou  lors  d’une  rupture  de  sonde.  Étude  monocentrique
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Summary
Background.  —  The  reported  failure  rate  of  the  Sprint  Fidelis  deﬁbrillator  lead  (SFDL)  has
increased more  than  initially  expected,  with  emerging  evidence  of  accelerating  fracture  rates.
Current consensus  guidelines  continue  to  discourage  prophylactic  lead  extraction,  citing  major
complication  rates  of  1.4—7.3%.  Therefore,  data  relating  to  the  risks  of  systematic  SFDL  extrac-
tion are  lacking,  with  no  methodical  extraction  protocol  reported  to  date.  Moreover,  few
statistical analyses  have  identiﬁed  predictors  of  SFDL  failure.Sprint  Fidelis  leads Objectives.  —  The  aims  of  this  single-centre  study  were:  to  examine  the  safety  and  feasibility
of systematic  SFDL  extraction  at  the  time  of  pulse  generator  replacement  or  in  case  of  lead
failure; and  to  identify  predictors  of  SFDL  failure.
Methods.  —  Between  January  2005  and  October  2007,  218  consecutive  patients  underwent
transvenous  SFDL  implantation  in  our  centre.
Abbreviations: Afssaps, Agence franc¸aise de sécurité sanitaire des produits de santé; ICD, implantable cardioverter-deﬁbrillator;
LVEF, left ventricular ejection fraction; RV, right ventricular; SFDL, Sprint Fidelis deﬁbrillator lead.
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Results.  —  During  a  mean  follow-up  of  43  ±  15  months,  SFDL  extraction  was  performed  in  49
patients  (22.5%)  for  the  following  reasons:  inappropriate  shocks  (n  =  21;  9.6%),  systematic
extraction  at  time  of  pulse  generator  extraction  (n  =  23;  10.5%),  high  impedance  (n  =  3;  1.4%),
high SFDL  threshold  (n  =  1;  0.4%)  and  cardiac  device-related  infection  (n  =  1;  0.4%).  No  severe
complications  occurred,  although  two  minor  complications  were  reported  (lead  dislodgments).
SFDL fracture  was  observed  in  25  patients  (11.5%;  3.2%/year  incidence).  The  only  predictor
associated  with  SFDL  fracture  was  the  number  of  leads  (P  =  0.01).
Conclusion.  —  In  our  series,  SFDL  extraction  at  the  time  of  pulse  generator  extraction  or  in  case
of evidence  of  lead  failure  was  feasible  and  safe.  Number  of  leads  was  identiﬁed  as  a  new
predictive  factor  for  SFDL  fracture.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Introduction.  —  Le  nombre  de  ruptures  des  sondes  de  déﬁbrillation  Sprint  Fidelis  (SDSF)  a  aug-
menté très  signiﬁcativement  au  cours  du  temps.  Les  recommandations  actuelles  sont  contre
l’extraction  systématique  de  ces  sondes  en  raison  d’un  pourcentage  de  complications  estimé
entre 1,4  et  7,3  %.  Cependant  les  travaux  concernant  les  extractions  de  SDSF  sont  peu  nombreux,
rétrospectifs  et  sans  protocole  préalable.
Objectifs.  —  Les  objectifs  de  cette  étude  sont  de  deux  ordres  :  premièrement,  évaluer  la  fais-
abilité et  la  sécurité  de  l’extraction  des  SDSF  lors  du  changement  de  boîtier  ou  lors  d’une
rupture de  sonde  ;  deuxièmement,  identiﬁer  les  facteurs  prédictifs  de  rupture  de  sondes.
Méthode  et  résultats.  —  Entre  janvier  2005  et  octobre  2007,  218  patients  ont  bénéﬁcié  de  la
mise en  place  d’une  SDSF  dans  notre  centre.  Au  cours  d’un  suivi  moyen  de  43  ±  15  mois,  une
extraction  de  SDSF  a  été  réalisée  chez  49  patients  (22,5  %)  pour  les  raisons  suivantes  :  chocs
inappropriés  chez  21  patients  (9,6  %),  une  extraction  systématique  au  cours  d’un  changement
de boîtier  chez  23  patients  (10,5  %),  une  impédance  élevée  chez  trois  patients  (1,4  %),  un  seuil
élevé pour  un  patient  (0,4  %)  et  une  infection  de  dispositif  chez  un  patient  (0,4  %).  Aucune
complication  majeure  n’a  été  constatée  et  deux  déplacements  de  sondes  ont  été  observés.
Une rupture  de  SDSF  a  été  observée  chez  25  patients  (11,5  %  ;  3,2  %  rupture  par  an),  et  le  seul
facteur prédictif  de  rupture  a  été  le  nombre  de  sondes  (p  =  0,01).
Conclusion.  — Dans  notre  série,  l’extraction  de  sondes  SDSF  au  moment  du  changement  de
boîtier ou  lors  d’une  rupture  de  sondes  est  faisable  avec  des  risques  limités.  Le  seul  facteur
prédictif de  rupture  était  le  nombre  de  sondes  implantées.
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ackground
he  Sprint  Fidelis  deﬁbrillator  lead  (SFDL)  (models
930,  6931,  6948  and  6949;  Medtronic  Inc.,  Minneapo-
is,  Minnesota)  is  a  6.6-F  bipolar  high-voltage  implantable
ardioverter-deﬁbrillator  (ICD)  lead  [1—8]. The  lead  was
pproved  by  the  United  States  Food  and  Drug  Administration
n  September  2004  and  approximately  268,000  leads  have
een  implanted  worldwide  [1].  However,  concerns  about
he  early  fracture  rate  of  the  lead  were  ﬁrst  reported  in
pril  2007  and  on  15  October  2007  the  manufacturer  sus-
ended  distribution  of  the  SFDL  [1—8]. The  reported  SFDL
ailures  have  increased  to  a  greater  extent  than  initially
xpected,  with  failure  rates  estimated  at  3.75%  per  year
ompared  with  the  reported  1.7%  per  year  in  Medtronic’s
ebruary  2010  update  registry  [8].  Current  consensus  guide-
ines  discourage  prophylactic  lead  extraction,  citing  major
omplication  rates  of  between  1.4  and  7.3%  [9].  Thus,
ecommendations  regarding  management  include  routine
onitoring  every  3  months  after  adjusting  impedance  alarm
hresholds  or  SFDL  extraction  in  patients  with  pacemakers  or
ith  conﬁrmed  or  suspected  SFDL  fractures  [9].  Two  major
ulticentre  surveys  recently  highlighted  the  risks  associated
p
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ith SFDL  extraction  in  this  clinical  setting.  Despite  the  large
umber  of  patients  included  in  both  multicentre  studies,
onclusions  remain  debatable  due  to  several  methodological
hortcomings,  such  as  retrospective  evaluation,  the  absence
f  a  systematic  approach  between  centres  and  no  long-term
ollow-up  [10,11].  Moreover,  only  a  few  studies  have  sought
o  identify  predictors  of  SFDL  fracture  [1,2,12].  Accordingly,
he  aim  of  this  single-centre  study  was  two-fold:  to  exa-
ine  the  safety  and  feasibility  of  systematic  SFDL  extrac-
ion  at  the  time  of  pulse  generator  replacement  or  in  case
f  evidence  of  lead  failure;  and  to  identify  predictors  of  SFDL
racture.
ethods
atient selection and implantation techniques
etween  January  2005  and  October  2007,  218  consecutive
atients  underwent  transvenous  SFDL  implantation.  Leads
ere  inserted  via  left-sided  or  right-sided  venous  access
y  cephalic  cutdown  or  via  subclavian  vein  access  using
tandard  techniques.  Leads  were  positioned  in  the  right
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ventricular  (RV)  apex.  Deﬁbrillation  safety  margins  as  well
as  pacing  and  sensing  thresholds  were  determined  accord-
ing  to  usual  practices  in  order  to  ensure  adequate  detection
and  termination  of  ventricular  tachyarrhythmias,  while  pro-
viding  rate  support  in  the  event  of  bradycardia.  Atrial
and  left  ventricular  leads  were  added  in  patients  requir-
ing  multichamber  pacing  and  sensing.  All  ICD  implantations
conducted  at  our  centre  were  recorded,  while  patient
follow-up  was  carried  out  in  our  outpatient  clinic.  The
SFDL  model  most  frequently  implanted  was  the  dual-coil
active-ﬁxation  lead  (model  6949),  followed  by  the  single-
coil  active-ﬁxation  lead  (model  6931).  All  patients  with  SFDL
were  identiﬁed,  with  details  on  any  lead  fractures  being
recorded  in  line  with  the  recommendations  of  the  Agence
franc¸aise  de  sécurité  sanitaire  des  produits  de  santé  (Afss-
aps).
Monitoring
In  accordance  with  the  manufacturers’  recommendations,
we  reprogrammed  devices  and  activated  alarms  in  order
to  provide  patients  with  a  warning  system  in  the  event  of
impedance  changes  suggesting  a  lead  fracture.
Endpoints
Lead  failure  was  deﬁned  as  non-physiological  high-rate
sensing  with  high  pacing  impedance  suggesting  a  fracture,
sudden  change  in  sensing  or  pacing  impedance,  or  rise  in
high-voltage  impedance  suggestive  of  coil  fracture,  resulting
in  the  decision  to  perform  lead  replacement.  Inappropri-
ate  shocks  due  to  sensing  of  electrical  noise  artefacts  from
make-break  potentials  were  also  deﬁned  as  SFDL  fractures.
At  the  time  of  pulse  generator  replacement,  SFDL  extrac-
tion  was  systematically  performed  in  all  patients  except  for
those  aged  80  years  or  more.
Data retrieval
Clinical  and  device  interrogation  data  were  retrieved  from
the  ICD  database.  Additional  data  were  obtained  from  local
clinical  records  and  from  the  ‘save  to  disk’  ﬁles  of  patients
with  Sprint  Fidelis  model  6949  lead  fractures.  Between
January  2008  and  May  2011,  each  patient  device  was  interro-
gated  every  3  months  in  the  outpatient  clinic  in  line  with  the
Afssaps  recommendations.  If  available,  telemonitoring  was
activated  and  data  were  analysed.  The  following  variables
were  examined  as  potential  predictors  of  lead  fracture:  age,
risk  factors,  sex,  vein  of  access  (cephalic  or  non-cephalic),
cardiomyopathy  aetiology,  number  of  electrodes  implanted,
device  type  (single  chamber,  double  chamber  or  resynchro-
nization),  weight  and  most  recent  left  ventricular  ejection
fraction  (LVEF).
Extraction
Surgical  reintervention  was  deﬁned  as  a  surgical  pro-
cedure  required  for  non-infectious  or  infectious  implant
complications.  The  extraction  was  performed  using  either
simple  traction  or  traction  devices.  Simple  traction  involved
manipulating  the  lead  so  that  it  left  the  vasculature  via
the  implant  vein  by  using  tools  typically  supplied  for  lead
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mplants,  with  the  addition  of  traction.  These  tools  included
tems  such  as  standard  stylets  (non-locking)  and  ﬁxation
crew  retraction  clips.  Traction  devices  involved  locking
tylets,  snares  and  sutures  as  well  as  grasping  or  other
evices  used  to  engage,  entrap  and  remove  the  lead  or
ead  fragments.  Locking  stylets  are  a  special  type  of  trac-
ion  device  designed  to  grasp  the  inside  of  the  conductor
oil  along  its  length  or  near  the  distal  stimulating  elec-
rode,  thus  improving  tensile  properties  and  preventing
longation  of  the  lead  body  during  traction  [9].  If  trac-
ion  alone  did  not  result  in  successful  lead  extraction,
 laser-powered  sheath  system  (Spectranetics  Inc.,  Col-
rado  Springs,  CO,  USA)  was  used.  Major  complications  were
eﬁned  as  the  following  events:  death;  cardiac  or  vascular
vulsion  or  tear  requiring  thoracotomy,  pericardiocentesis,
hest  tube  or  surgical  repair;  pulmonary  embolism  requir-
ng  surgical  intervention;  respiratory  arrest  or  anaesthesia
omplications  leading  to  prolongation  of  hospitalization;
troke;  and  pacing  system-related  infection  of  a  previously
on-infected  site.  Minor  complications  were  deﬁned  as:
ericardial  effusion  not  requiring  pericardiocentesis  or  sur-
ical  intervention;  haemothorax  not  requiring  a  chest  tube;
aematoma  at  the  surgical  site  requiring  reoperation  for
rainage;  arm  swelling  or  thrombosis  of  implant  veins  neces-
itating  medical  intervention;  haemodynamically  signiﬁcant
ir  embolism;  migrated  lead  fragment  without  sequelae;
lood  transfusion  related  to  blood  loss  during  surgery;  pneu-
othorax  requiring  a  chest  tube;  and  pulmonary  embolism
ot  requiring  surgical  intervention.  Patients  were  followed
p  in  hospital,  with  30-day  procedure-related  outcomes
eing  reported.
ollow-up
n  line  with  the  Afssaps  recommendations,  the  collected
rospective  data  included:  patient  demographic  and  clini-
al  characteristics;  echocardiographic  measurements;  type
f  implanted  device  and  number  of  leads;  deﬁbrillator
nterrogation;  and  occurrence  of  complications  requiring
eintervention.  Patients  were  followed  up  by  four  experi-
nced  cardiologists.  Electrocardiograms  and  device  controls
ere  performed  the  day  after  the  procedure  and  immedi-
tely  before  patient  discharge.  Patients  were  examined  in
he  outpatient  clinic  every  3  months,  with  a  physical  exam-
nation  and  device  interrogation  being  carried  out  at  these
isits,  in  addition  to  weekly  telemonitoring.
tatistical analysis
ll  clinical  variables  were  assessed  at  the  time  of
evice  implantation,  with  continuous  variables  expressed
s  mean  ±  standard  deviation.  Comparisons  of  continuous
ariables  between  the  patient  groups  were  conducted  using
he  unpaired  Student’s  t  test  or  the  Mann-Whitney  test
s  appropriate.  Categorical  variables  were  compared  using
he  chi-square  test  or  Fisher’s  exact  test  as  appropriate.
he  cumulative  risk  of  SFDL  fracture  was  interpreted  using
aplan-Meier  curves  and  analysed  by  means  of  the  log-rank
est.  Univariate  analysis  was  ﬁtted  in  order  to  investigate
he  relationship  between  each  covariate  and  the  risk  of
FDL  fracture.  Backward  elimination  was  also  used,  remov-
ng  the  least  signiﬁcant  variables  at  each  step  to  elaborate
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Table  1  Patient  characteristics  (n  =  218).
Characteristic
Mean  age  ±  SD  (years)  66  ±  11
Female  (%)  15.1
Hypertension  (%) 41
Diabetes  mellitus  (%) 24
Hypercholesterolaemia  (%)  42
Tobacco  smoker  (current  or  past)  (%)  54
Cause  of  cardiomyopathy  (%)
Idiopathic  dilated  cardiomyopathy  56.4
Ischaemic  cardiomyopathy  43.6
Indication  (%)
Primary  prevention  26.1
Secondary  prevention  24.8
Cardiac  resynchronization  49.1
Device  implanted  (%)
Single  chamber  23.9
Double  chamber  22.5
Cardiac  resynchronization  therapy  53.6
Mean  LVEF  ±  SD  (%)  29  ±  6
Venous  access  (%)
Cephalic  78.5
Subclavian  11.5
SFDL  active  ﬁxation  202
SFDL  passive  ﬁxation  16
Mean  number  of  leads/patient  ±  SD  2.2  ±  0.8
LVEF: left ventricular ejection fraction; SD: standard deviation;
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fracture  group  concerning  other  variables,  including  age,SFDL: Sprint Fidelis deﬁbrillator lead.
ultivariable  models  if  necessary.  A  probability  value  of
 <  0.05  was  considered  statistically  signiﬁcant.  All  analyses
ere  performed  using  StatView® 5.0  (StatView  IV;  Abacus
oncept,  Berkeley,  CA,  USA).
esults
aseline population characteristics
aseline  clinical  data  are  summarized  in  Table  1.  The
redominant  Sprint  Fidelis  lead  model  extracted  was  the
ual-coil  active-ﬁxation  lead  (model  6949;  n  =  200,  91.7%),
ollowed  by  the  dual-coil  passive-ﬁxation  lead  (model  6948;
 =  15,  6.8%),  then  the  single-coil  active-ﬁxation  lead  (model
931;  n  =  2,  1.0%)  and  lastly,  the  single-coil  passive-ﬁxation
ead  (model  6930;  n  =  1,  0.5%).
urvival of patients with SFDL and predictive
actors for  SFDL fracture
etween  January  2005  and  October  2007,  218  consecutive
atients  underwent  transvenous  SFDL  implantation.  Dur-
ng  a  follow-up  of  43  ±  15  months  (range:  23  to  72  months),
5  patients  died  (20.6%;  5.7%/year  incidence;  mean  age:
6.5  ±  8  years),  six  were  transplanted  (2.8%)  and  eight
ere  lost  to  follow-up  (3.7%).  Among  the  45/218  patients
ho  died,  causes  of  death  were  as  follows:  heart  failure
n  =  24;  11%);  sudden  death  (n  =  4;  1.8%);  acute  mesenteric
L
T
aigure 1. Sprint Fidelis population. SFDL: Sprint Fidelis deﬁbril-
ator lead.
schaemia  (n  =  3;  1.4%);  infection  disease  (n  =  3;  1.4%);  ter-
inal  kidney  failure  (n  =  2;  0.9%);  fatal  car  crash  (n  =  2;
.9%);  epilepsy-related  death  (n  =  1;  0.5%);  electrical  storm
n  =  1;  0.5%);  prostate  cancer  (n  =  1;  0.5%);  and  unknown
n  =  4;  1.8%).  SFDL  extraction  was  performed  in  49  patients
22.5%)  for  the  following  reasons:  inappropriate  shocks
appearance  of  non-physiological  short  V-V  intervals)  (n  =  21;
.6%);  systematic  extraction  at  the  time  of  pulse  genera-
or  extraction  (n  =  23;  10.5%);  high  impedance  (n  =  3;  1.4%);
igh  SFDL  threshold  (n  =  1;  0.4%);  and  cardiac  device-related
nfection  (n  =  1;  0.4%)  (Fig.  1).  Device  impedance  alarm  pro-
ramming  was  implemented  and  programmed  at  nominal
evels  (>  2500  ).  After  hearing  alarms,  three  patients  con-
ulted  our  centre,  thereby  avoiding  inappropriate  shocks.
mong  patients  with  SFDL  extraction,  fracture  was  observed
n  25  patients  (11.5%;  3.2%/year  incidence)  (Fig.  2).  The
xtraction  procedure  was  performed  using  a  simple  trac-
ion  in  two  patients  (4.4%),  a  locking  stylet  in  46  patients
93.8%)  and  a  laser-powered  sheath  system  in  one  patient
2.2%).  Although  no  severe  complications  were  noted  fol-
owing  extraction,  two  minor  complications  occurred  (two
ead  dislodgments).
The  number  of  leads  was  the  only  predictor  associated
ith  SFDL  fracture  (P  =  0.01)  (Table  2).  There  were  no  dif-
erences  between  the  SFDL  fracture  group  and  the  non-SFDLVEF,  cardiomyopathy  aetiology  and  venous  access  (Table  2).
here  were  no  differences  between  the  SFDL  fracture  group
nd  the  systematic  SFDL  extraction  group  (Table  3).
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Table  2  Comparison  of  patient  characteristics  in  the  SFDL  fracture  and  non-SFDL  fracture  groups.
SFDL  fracture  (n  =  25)  Non-SFDL  fracture  (n  =  193)  P
Mean  age  ±  SD  (years) 64  ±  14  66  ±  11  0.4
Women  (%)  12  14.5  0.9
Mean  LVEF  ±  SD  (%)  27  ±  5  29  ±  4  0.1
Cause  of  cardiomyopathy
Dilated  cardiomyopathy 16  (64)  107  (55.4)  0.5
Ischaemic  cardiomyopathy 9  (36) 86 (44.6)
Indication
Primary  prevention 2  (7) 55 (28.5)
Secondary  prevention  6  (25)  48  (24.9)  0.1
Cardiac  resynchronization  17  (68)  90  (46.6)
Device  implanted
Single  chamber  2  (7.1)  50  (26)  0.1
Double  chamber  4  (16.4)  45  (23.3)
Cardiac  resynchronization  19  (76.5)  98  (50.7)
Venous  access
Cephalic  21  (84)  150  (77.7)  0.5
Subclavian  4  (16)  43  (22.3)
Mean  number  of  leads  2.6  2.1  0.008
Data are number (%), unless otherwise indicated. LVEF: left ventricular ejection fraction; SD: standard deviation; SFDL: Sprint Fidelis
deﬁbrillator lead.
Table  3  Comparison  of  patient  characteristics  in  the  SFDL  fracture  and  systematic  SFDL  extraction  groups.
SFDL  fracture  (n  =  25)  Systematic  SFDL  extraction  (n  =  24)  P
Mean  age  ±  SD  (years)  64  ±  14  66  ±  9  0.4
Women  (%)  12  16.6  0.9
Mean  LVEF  ±  SD  (%)  27  ±  8  31  ±  9  0.08
Cause  of  cardiomyopathy
Dilated  cardiomyopathy  16  (64)  18  (75)  0.6
Ischaemic  cardiomyopathy  9  (36)  6  (25)
Indication
Primary  prevention 2  (7)  5  (21)  0.3
Secondary  prevention 6  (25) 7 (29)
Cardiac  resynchronization 17  (68)  12  (50)
Device  implanted
Single  chamber  2  (7.1)  4  (17)  0.4
Double  chamber 4  (16.4)  6  (25)
Cardiac  resynchronization 19  (76.5) 14  (58)
Venous  access
Cephalic  21  (84)  16  (67)  0.3
Subclavian  4  (16)  8  (23)
Mean  number  of  leads  ±  SD  2.6  ±  0.6  2.2  ±  0.7  0.1
Type  of  extraction
Simple  traction  1  1
Locking  stylet  23  23  0.9
Laser-powered  sheath  system  1  0
Data are number (%), unless otherwise indicated. LVEF: left ventricular ejection fraction; SD: standard deviation; SFDL: Sprint Fidelis
w
odeﬁbrillator lead.
DiscussionComparative studies regarding SFDL extraction
Our  study  has  provided  additional  data  about  the  safety
and  feasibility  of  transvenous  SFDL  extraction,  especially
i
t
d
phen  coinciding  with  pulse  generator  replacement.  Based  on
ur  experience,  complete  procedural  success  was  observed
n  all  cases  regardless  of  the  method  of  SFDL  extrac-
ion,  with  no  major  complications  or  procedure-related
eaths.  Our  results  are  in  agreement  with  the  recently
ublished  work  by  Maytin  et  al.,  who  reported  no  major
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Clinical implicationsigure 2. Kaplan-Meier curve: lead survival. SFDL: Sprint Fidelis
eﬁbrillator lead.
rocedural  complications  or  deaths  [10]. In  contrast,  a  Cana-
ian  national  survey  reported  a  SFDL  failure  rate  of  4.97%
t  40  months,  with  an  overall  complication  rate  of  14.5%  for
ead  revisions,  classiﬁed  into  7.25%  major  and  7.25%  minor
omplications  [11]; in  addition,  two  deaths  (0.43%)  were
eported.  In  this  study,  the  overall  risk  of  complications
14.5%)  was  shown  to  be  signiﬁcantly  higher  in  patients
ndergoing  lead  removal  at  the  time  of  revision  than  in
hose  with  abandoned  leads  (8.6%;  P  <  0.0008).  The  prog-
osis  discrepancy  between  these  two  published  studies  may
e  accounted  for  by  differing  experience  levels,  with  the
anadian  registry  centres  being  less  experienced  and  tend-
ng  to  use  the  laser  lead  extraction  method  [9,11—13].  Leads
hat  were  extracted  at  an  early  time  following  implanta-
ion  were  presumably  easier  to  remove  than  older  leads,
hich  were  more  likely  to  require  formal  extraction,  result-
ng  in  an  increased  rate  of  complications  (40  vs  27.9  months)
10,11].  However,  in  our  experience,  SFDLs  were  removed
fter  a  long-term  follow-up  of  38  ±  14  months,  without
omplications.  Accordingly,  the  management  of  patients
ith  an  implanted  SFDL  is  still  challenging.  In  the  setting  of
 device-related  infection,  patient  management  is  based  on
 straightforward  decision  to  extract  the  device.  However,
n  cases  of  fractured  or  functional  SFDLs,  the  management
f  non-infected  patients  appears  to  be  more  difﬁcult.  Pre-
ious  treatment  options  included  adding  a  new  pace-sense
ead.  However,  this  approach  is  no  longer  recommended
y  Medtronic  due  to  the  risk  of  subsequent  high-voltage
onduction  failure.  The  risks  associated  with  each  of  these
ptions  must  be  carefully  judged  on  a  case-by-case  basis,
s  recommended  in  the  2009  Heart  Rhythm  Society  expert
onsensus  document  on  transvenous  lead  extraction  and
s  advised  by  the  French  Afssaps  [9].  The  essential  ques-
ion  presently  is  how  to  optimize  patient  management.  The
nitial  letter  addressed  to  physicians  issued  the  following
ecommendations:  turning  on  patient  alert  for  RV  pac-
ng,  RV  deﬁbrillation  and  superior  vena  cava  deﬁbrillation
mpedance;  programming  ventricular  ﬁbrillation  detection
or  the  initial  number  of  intervals  to  detect  to  nominal  set-
ings  (18/24)  or  longer  at  the  discretion  of  the  physician,
nd  for  the  number  of  intervals  to  redetect  to  nominal  set-
ings  (12/16);  reviewing  ventricular  pacing  lead  impedance
M
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rends  and  programming  lead  impedance  alert  for  RV  pacing;
nd  conducting  3-month  evaluations  in  the  outpatient  clinic
9].  Several  factors  are  associated  with  low-risk  SFDL  extrac-
ion,  including  small  lead  diameter,  ﬁxation  screw  retraction
echanism  and  short  time  interval  from  implantation  to
emoval.  Maytin  et  al.  reported  average  lead  implanta-
ion  duration  of  27.5  months,  with  49.4%  of  the  extracted
eads  being  fractured  and  26.5%  being  extracted  prophylac-
ically.  Another  major  indication  for  extraction  was  infection
22.8%).  Extraction  was  achieved  with  simple  traction  in
9.4%  leads,  the  use  of  counter  traction  sheath  assistance
eing  required  in  174  cases  (50.6%)  without  laser.  In  our  reg-
stry,  laser  was  used  in  one  case  only,  whereas  a  locking
tylet  was  systematically  employed  for  SFDL  extraction  at
he  time  of  pulse  generator  replacement.  The  absence  of
ajor  complications  supports  this  strategy.
redictive factors for SFDL fracture
he  underlying  mechanisms  that  cause  Sprint  Fidelis  and
print  Quattro  fractures  are  still  unclear.  Three  factors  are
ikely  to  contribute  to  ICD  lead  fracture:  lead  construc-
ion;  implantation  technique;  and  patient-related  features.
o  date,  few  clinical  factors  have  been  identiﬁed  as  pre-
ictors  of  fracture,  with  cephalic  vein  access  reducing  the
isk  compared  with  subclavian  access,  as  well  as  LVEF  [2].
wo  recent  case  series  suggested  that  younger  age  may  be
 key  variable,  perhaps  linked  to  more  vigorous  cardiac
otion  or  increased  physical  activity  [1,12]. More  recently,
 larger  series  study  demonstrated  that  compared  with
print  Quattro  leads,  the  survival  of  SFDL  continued  to
ecline,  with  the  SFDL  failure  rate  being  notably  higher
n  younger  patients,  women,  subjects  with  hypertrophic
ardiomyopathy  and  patients  with  arrhythmogenic  right  ven-
ricular  dysplasia  or  channelopathies  [14]. These  ﬁndings
ave  signiﬁcant  implications  for  managing  SFDL  patients,  as
hey  show  the  relevance  of  weighing  clinical  variables  when
ssessing  ICD  lead  performance  [14].
Our  centre  is  the  ﬁrst  to  report  that  the  risk  of  frac-
ure  is  dependent  on  the  number  of  leads  implanted,  being
igher  for  patients  with  two  or  more  leads,  as  is  the  case  for
esynchronization  therapy.  In  general,  failure  mechanisms
f  ICD  leads  may  involve  shocking  coils  or  the  pace-sense
lectrodes.  The  two  major  failure  modes  of  SFDL  relate  to
ace-sense  conductor  fractures,  affecting  either  the  cable
o  the  anode  (ring  electrode)  near  the  tip  of  the  lead  or
he  coil  to  the  cathode  (tip  electrode)  near  the  anchoring
leeve  [14—19]. These  fractures  are  most  commonly  present
ith  rapid  oversensing,  resulting  in  inappropriate  shocks.
hey  may  also  present  as  failure  to  deliver  bradycardia  or
ntitachycardia  pacing  due  to  elevated  impedance  or  pac-
ng  inhibition  by  oversensing.  Fracture  of  the  high-voltage
lectrode  occurs  less  frequently  [14—19]. Although  never
escribed  before,  the  mechanism  linked  to  the  number  of
eads  may  be  due  to  interlead  friction,  which  is  likely  to  lead
o  constraints,  traction,  friction,  wear  and  ﬁnally  resulting
n  pace-sense  conductor  fractures.anaging  patients  with  SFDL  remains  challenging.  To  pre-
ent  complications  such  as  inappropriate  shocks,  failure
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of  stimulation  or  death,  systematic  SFDL  extraction  is
favoured.  Conversely,  recommendations  regarding  manage-
ment  include  routine  monitoring  after  adjusting  impedance
alarm  thresholds.  According  to  Medtronic  and  its  Indepen-
dent  Physician  Quality  Panel,  the  current  failure  rate  is
estimated  at  0.92%  per  year,  which  appears  insufﬁcient
to  justify  prophylactic  lead  replacement,  given  the  major
complication  rates  of  extraction  of  between  1.4%  and  7.3%
[7,8,11,20—23].  In  our  series,  we  report  a  higher  inci-
dent  risk  of  3.2%  SFDL  fractures  per  year,  with  a  very  low
level  of  complications  related  to  SFDL  extraction,  partic-
ularly  in  cases  when  systematic  extraction  was  performed
at  the  time  of  pulse  generator  replacement.  Our  study  sup-
ports  the  approach  of  extracting  SFDL  as  early  as  possible,
thereby  avoiding  the  higher  risks  associated  with  extraction
on  long-term  follow-up.  This  approach  is  in  line  with  the
observations  of  Maytin  et  al.  [10], provided  that  the  extrac-
tion  is  performed  by  experienced  operators,  thus  preventing
the  problems  associated  with  abandoned  leads  on  long-term
follow-up  [10,11,24—35].
Study limitations
Our  study  has  several  limitations.  Although  a  retrospective
design  was  used  for  evaluating  predictive  factors,  syste-
matic  extraction  at  the  time  of  pulse  generator  replace-
ment  was  carried  out  prospectively.  No  data  on  the  site  of
lead  fracture  in  our  individual  cases  were  available  and  as
our  sample  size  as  regards  SFDL  extraction  was  small,  sys-
tematic  extraction  needs  to  be  further  assessed  in  a  larger
patient  population.  Regarding  the  advantages  of  our  study,
our  follow-up  is  the  longest  published  to  date  in  this  ﬁeld,
with  a  routine  examination  being  performed  every  3  months.
In  addition,  our  ﬁndings  relating  to  systematic  SFLD  extrac-
tion  at  the  time  of  pulse  generator  replacement  provide
supporting  evidence  for  this  kind  of  approach.
Conclusion
SFDL  extraction  at  the  time  of  pulse  generator  extraction
or  in  the  case  of  evidence  of  lead  failure  was  shown  to  be
feasible  and  safe.  The  number  of  leads  was  the  only  new
predictor  of  SFDL  fracture  identiﬁed.
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